Fig. 1 · Structure

Documents & Downloads

Simeprevir

Cat. No. A11580 CAS 923604-59-5

HCV NS3/4A protease inhibitor

Simeprevir is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HT-1080 CC50 16 μM Cytotoxicity against human HT1080 cells after 3 to 4 days by resazurin proliferation assay [PMID: 19171797]
Huh-7 EC50 1.4 nM Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay [PMID: 21067923]
Huh-7 EC50 11 nM Antiviral activity against Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 11 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R109K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 12 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80L mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 13 nM Antiviral activity against Hepatitis C virus 1b infected in human HuH7 cells assessed as viral RNA level after 72 hrs by quantitative reverse transcriptase PCR [PMID: 19171797]
Huh-7 EC50 1362 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80H and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 16867 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and D168A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 17917 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 18 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36L mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 18 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q41R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 1815 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S and Q80R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 2.3 nM Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay [PMID: 21067923]
Huh-7 EC50 2.7 nM Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay [PMID: 20855726]
Huh-7 EC50 20 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36M mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 20.1 nM Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay [PMID: 20855726]
Huh-7 EC50 206 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 21 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155Q mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]
Huh-7 EC50 2149 nM Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay [PMID: 20176898]

19 records · Scroll to view more

Simeprevir Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Simeprevir from 3 published references. In vitro models include Vero E6; Vero E6 cells.

Simeprevir In Vitro Studies

In Vero E6 cells, Simeprevir yielded an EC50 of 4.08 μM based on SARS-CoV-2 ORF1b copy number in culture supernatant, with DMSO as the negative control. In a separate comparison, 10 μM Simeprevir inhibited SARS-CoV-2 antigen expression relative to its absence. Cell viability measurements in Vero E6 cells yielded a CC50 of 19.33 μM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Antiviral activity in Vero E6 cells

Cell-based study · Vero E6 [1]

Vero E6 cells received varying concentrations of Simeprevir, with DMSO as the negative control. Quantification of SARS-CoV-2 ORF1b copy number in culture supernatant yielded an EC50 of 4.08 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
quantification of SARS-CoV-2 ORF1b copy number in the culture supernatantEC50 4.08 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
varying concentrations
Exposure duration
1 h before infection, during infection, and 48 h after infection
Method
present in the supernatant
Vehicle
DMSO
Co-treatment
Other interventions in this design: SCoV2 multiplicity of infection (MOI) of 0.05. Compound effect isolated by the comparison: DMSO as the vehicle was used as a negative control.
Methods and source locations

Compound reported in the paper: Simeprevir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Prioritized Screening Identifies Simeprevir As a Potent Suppressor of SARS-CoV-2 Replication in a Cellular Infection Model (S4, S6); Materials and Methods > In Vitro SARS-CoV-2 Antiviral Tests (S44, S45, S46, S47); Materials and Methods > In Vitro PLpro Inhibition Assay—Fluorescence-Based (S94); Figure 2 legend (S129)

quantification of SARS-CoV-2 ORF1b copy number in the culture supernatant: quantification of SARS-CoV-2 ORF1b copy number in the culture supernatant; comparator: DMSO as the vehicle was used as a negative control — Results > Prioritized Screening Identifies Simeprevir As a Potent Suppressor of SARS-CoV-2 Replication in a Cellular Infection Model (S6); Materials and Methods > In Vitro SARS-CoV-2 Antiviral Tests (S47)

Viral antigen expression in Vero E6 cells

Cell-based study · Vero E6 cells [2]

Vero E6 cells were exposed to SARS-CoV-2 in the presence or absence of 10 μM Simeprevir. Simeprevir inhibited the expression of SARS-CoV-2 antigens.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of SARS-CoV-2 antigensReported result inhibitory impact of simeprevir on the expression of SARS-CoV-2 antigens[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
24 h
Method
SARS-CoV-2 virus was then added to the cells in the presence or absence of 10 μM simeprevir.
Vehicle
dimethyl sulfoxide (DMSO)
Co-treatment
Other interventions in this design: SARS-CoV-2 MOI of 0.01. Compound effect isolated by the comparison: in the presence or absence of 10 μM simeprevir.
Methods and source locations

Compound reported in the paper: Simeprevir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cells, compounds and virus (S3); Materials and methods > Immunofluorescence assay (S24, S25, S26, S27, S28, S29, S30); Fig. 1 legend (S51)

expression of SARS-CoV-2 antigens: expression of SARS-CoV-2 antigens; comparator: absence of 10 μM simeprevir — Materials and methods > Immunofluorescence assay (S24)

Cytotoxicity in Vero E6 cells

Cell-based study · Vero E6 cells [1]

Vero E6 cells received Simeprevir at the indicated concentrations. Cell viability measured by colorimetric absorbance yielded a CC50 of 19.33 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was quantified with colorimetric absorbance at 590 nmCC50 19.33 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
indicated concentrations
Exposure duration
48 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route, control.
Methods and source locations

Compound reported in the paper: Simeprevir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Prioritized Screening Identifies Simeprevir As a Potent Suppressor of SARS-CoV-2 Replication in a Cellular Infection Model (S6); Materials and Methods > Chemicals and Reagents (S41); Materials and Methods > In Vitro Drug Cytotoxicity Assays (S62, S63, S64)

Cell viability was quantified with colorimetric absorbance at 590 nm: Cell viability was quantified with colorimetric absorbance at 590 nm — Results > Prioritized Screening Identifies Simeprevir As a Potent Suppressor of SARS-CoV-2 Replication in a Cellular Infection Model (S6); Materials and Methods > In Vitro Drug Cytotoxicity Assays (S64)

Simeprevir In Vivo Studies

Female SCID mice bearing kill switch-transduced HT29 xenografts received oral Simeprevir at 200 mg/kg, with an untreated group as the negative control. Complete tumor regression occurred in all treated mice, regardless of tumor size at dosing. [3]

Tumor regression in kill switch-transduced xenografts

Animal study · Female SCID mice (C.B-17/IcrHan®Hsd-Prkdcscid strain); kill switch-transduced HT29 xenograft mouse model; 8 mice per group [3]

Female SCID mice bearing kill switch-transduced HT29 xenografts received oral Simeprevir at 200 mg/kg, with an untreated group as the negative control. Complete tumor regression occurred in all treated mice, regardless of tumor size at dosing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume was measured 3 times per week with callipersReported result complete regression of the tumors in all mice, regardless of tumor size at dosing, after a single dose of simeprevir, with tumors remaining undetectable up to three weeks after dosing[3]

Conditions shared by the study groups

Route
orally
Treatment course
a single dose; 250 mm3 (day 22)
Vehicle
polyvinylpyrollidone (PVP K30) was reconstituted in water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Simeprevir 200 mg/kgOne group was untreated as a negative control.complete regression of the tumors in all mice, regardless of tumor size at dosing, after a single dose of simeprevir, with tumors remaining undetectable up to three weeks after dosing[3]
Simeprevir 200 mg/kg
Model: Female SCID mice (C.B-17/IcrHan®Hsd-Prkdcscid strain); kill switch-transduced HT29 xenograft mouse model; 8 mice per group
Methods and source locations

Compound reported in the paper: Simeprevir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > The PRSIM-based CID system can induce cell killing in a xenograft mouse model (S124, S126); Methods > SPR-binding kinetics analysis (S213, S215); Methods > Transcriptional regulation assays (S230); Methods > HT29 xenograft study (S301, S307, S309, S311, S312, S313, S314)

Tumor volume was measured 3 times per week with callipers: Tumor volume was measured 3 times per week with callipers; comparator: One group was untreated as a negative control. — Results > The PRSIM-based CID system can induce cell killing in a xenograft mouse model (S124); Methods > HT29 xenograft study (S309)

Simeprevir 200 mg/kg · Results > The PRSIM-based CID system can induce cell killing in a xenograft mouse model (S124); Methods > HT29 xenograft study (S312)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 923604-59-5
Applications HCV NS3/4A protease inhibitor
Formula C38H47N5O7S2
Molecular Weight 749.96
Synonyms TMC435; TMC435350
SMILES
COC1=CC=C(C(O[C@H]2CC(C(N(C)CCCC/C=C\[C@H]3C[C@@]3(C(NS(=O)(C4CC4)=O)=O)NC5=O)=O)[C@H]5C2)=CC(C6=NC(C(C)C)=CS6)=N7)C7=C1C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (120.01 mM)
Water Insoluble
Ethanol 4 mg/mL (5.33 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Simeprevir Research References

  1. [1] Lo HS, Hui KPY, Lai HM, et al. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. ACS Cent Sci (2021). PMID: 34075346 DOI: 10.1021/acscentsci.0c01186 Source material
  2. [2] Muturi E, Hong W, Li J, et al. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice. Int J Antimicrob Agents (2022). PMID: 34929295 DOI: 10.1016/j.ijantimicag.2021.106499 Source material
  3. [3] Chin SE, Schindler C, Vinall L, et al. A simeprevir-inducible molecular switch for the control of cell and gene therapies. Nat Commun (2023). PMID: 38012128 DOI: 10.1038/s41467-023-43484-9 Source material

Added to your cart

View Cart Checkout
Loading...